NCT00210834View on ClinicalTrials.gov

An Efficacy and Safety Study of Epoetin Alfa (PROCRIT) Initiated at 40,000 Units Every Week Versus 80,000 Units Every Two Weeks in Anemic Patients With Cancer Receiving Chemotherapy.

PHASE2CompletedINTERVENTIONAL
Enrollment

310

Participants

Timeline

Start Date

May 31, 2004

Study Completion Date

September 30, 2005

Conditions
Anemia
Interventions
DRUG

epoetin alfa

All Listed Sponsors
collaborator

Ortho Biotech Products, L.P.

INDUSTRY

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00210834 - An Efficacy and Safety Study of Epoetin Alfa (PROCRIT) Initiated at 40,000 Units Every Week Versus 80,000 Units Every Two Weeks in Anemic Patients With Cancer Receiving Chemotherapy. | Biotech Hunter | Biotech Hunter